People with SzPD may not regard a lack of social-status or successful relationships, for example, as a harm. Furthermore, correlation with negative outcomes does not necessarily demonstrate that these outcomes were directly caused by the schizoidal traits. Rather, it may be that these outcomes are the result of discrimination against people with SzPD, who may be viewed as abnormal. Treatment
People with SzPD rarely seek treatment for their condition. This issue is found in many personality disorders, which prevents many people with these conditions from seeking treatment: they tend to view their condition as not conflicting with their self-image and their abnormal perceptions and behaviors as rational and appropriate. There are little data on the effectiveness of various treatments on this personality disorder because it is seldom seen in clinical settings. However, those in treatment have the option of medication and psychotherapy. Medication
No medications are indicated for directly treating SzPD, but certain medications may reduce the symptoms of SzPD as well as treat co-occurring mental disorders. The symptoms of SzPD mirror the negative symptoms of schizophrenia, such as anhedonia, blunted affect and low energy, and SzPD is thought to be part of the "schizophrenic spectrum" of disorders, which also includes the schizotypal and paranoid personality disorders, and may benefit from the medications indicated for schizophrenia. Originally, low doses of atypical antipsychotics like risperidone or olanzapine were used to alleviate social deficits and blunted affect.
"Latency to REM sleep and percentages of light sleep and REM sleep were normal, compared with normal ranges." Despite this, one study has found increased sleep fragmentation in patients with IH without long sleep time, suggesting multiple possible presentations.Per ICSD-3, five criteria must be met for a diagnosis of IH:

Daytime lapses into sleep or an irrepressible need to sleep on a daily basis, for at least 3 months
Absence of insufficient sleep syndrome
Absence of cataplexy
Absence of other causes of hypersomnia
The presence of positive MSLT tests.The latest ICD 10 defines IH with long sleep time as a neurological disorder that is a rare sleep disorder characterized by prolonged sleep at night and extreme sleepiness during the day. There are no apparent causes. This disorder affects the ability to function. It is of central nervous system origin characterized by prolonged nocturnal sleep and periods of daytime drowsiness. Affected individuals experience difficulty with awakening in the morning and may have associated sleep drunkenness, automatic behaviors, and memory disturbances. This condition differs from narcolepsy in that daytime sleep periods are longer, there is no association with cataplexy, and the multiple sleep latency onset test does not record sleep-onset rapid eye movement sleep. Management
Since the underlying mechanism is not yet fully understood, treatment efforts have usually focused on symptom management. In August 2021, low-sodium oxybate (Xywav) became the first U.S. FDA-approved treatment for idiopathic hypersomnia. Wake-promoting medications used in narcolepsy are also commonly used off-label to help manage the excessive daytime sleepiness of IH.